SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001437749-22-028272
Filing Date
2022-12-01
Accepted
2022-12-01 16:34:39
Documents
13
Period of Report
2022-11-30
Items
Item 8.01: Other Events

Document Format Files

Seq Description Document Type Size
1 FORM 8-K dffn20221201_8k.htm   iXBRL 8-K 28460
  Complete submission text file 0001437749-22-028272.txt   161621

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA dffn-20221130.xsd EX-101.SCH 3601
3 XBRL TAXONOMY EXTENSION DEFINITION LINKBASE dffn-20221130_def.xml EX-101.DEF 11532
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE dffn-20221130_lab.xml EX-101.LAB 15414
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE dffn-20221130_pre.xml EX-101.PRE 11688
7 EXTRACTED XBRL INSTANCE DOCUMENT dffn20221201_8k_htm.xml XML 2577
Mailing Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902
Business Address 300 EAST MAIN STREET SUITE 201 CHARLOTTESVILLE VA 22902 (434) 220-0718
Diffusion Pharmaceuticals Inc. (Filer) CIK: 0001053691 (see all company filings)

IRS No.: 300645032 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-37942 | Film No.: 221439245
SIC: 2834 Pharmaceutical Preparations